AIG-Onco2

AIG-Onco2 is an investigational oncolytic virus therapy being developed for the treatment of various solid tumors. It is engineered from a modified herpes simplex virus (HSV) designed to selectively replicate within and destroy malignant cells while sparing healthy tissue. The virus is typically modified to enhance its immunogenicity, often by expressing therapeutic transgenes such as cytokines (e.g., GM-CSF) that stimulate a systemic anti-tumor immune response. By inducing local cell lysis, AIG-Onco2 releases tumor-associated antigens into the microenvironment, potentially turning "cold" tumors "hot" and improving the efficacy of concurrent immunotherapies like checkpoint inhibitors.